These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16240890)

  • 21. Inequalities in health: access to treatment for HIV/AIDS.
    Giuliano M; Vella S
    Ann Ist Super Sanita; 2007; 43(4):313-6. PubMed ID: 18209264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries.
    Vento S; Lanzafame M; Lattuada E; Cainelli F; Restelli U; Foglia E
    Trop Med Int Health; 2013 Jan; 18(1):40-4. PubMed ID: 23094787
    [No Abstract]   [Full Text] [Related]  

  • 24. Three million HIV/AIDS sufferers could receive anti-retroviral therapy by 2005: new hope for those in developing world.
    Lepr Rev; 2002 Sep; 73(3):295-6. PubMed ID: 12449898
    [No Abstract]   [Full Text] [Related]  

  • 25. Access for all?
    Lange JM; Thaineua V
    Science; 2004 Jun; 304(5679):1875. PubMed ID: 15218109
    [No Abstract]   [Full Text] [Related]  

  • 26. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
    James JS
    AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002.
    Fischer A; Karasi JC; Kibibi D; Omes C; Lambert C; Uwayitu A; Hemmer R; Ende J; Schmit JC; Arendt V
    HIV Med; 2006 Jan; 7(1):64-6. PubMed ID: 16313295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The (political) economics of antiretroviral treatment in developing countries.
    Nattrass NJ
    Trends Microbiol; 2008 Dec; 16(12):574-9. PubMed ID: 18964022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adherence to antiretroviral therapy during HIV infection, a multidisciplinary approach].
    Slama L; Le Camus C; Amiel C; Pialoux G; Gharakhanian S
    Med Mal Infect; 2006 Jan; 36(1):16-26. PubMed ID: 16325363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving access to essential drugs for people living with HIV/AIDS.
    Balasubramaniam K
    Issues Med Ethics; 2000; 8(1):26-7. PubMed ID: 16323335
    [No Abstract]   [Full Text] [Related]  

  • 31. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
    Bennett DE
    Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenge and co-operation: civil society activism for access to HIV treatment in Thailand.
    Ford N; Wilson D; Cawthorne P; Kumphitak A; Kasi-Sedapan S; Kaetkaew S; Teemanka S; Donmon B; Preuanbuapan C
    Trop Med Int Health; 2009 Mar; 14(3):258-66. PubMed ID: 19207173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activism today: the Coalition for Salvage Therapy. Interview with Linda Grinberg. Interview by John S. James.
    Grinberg L
    AIDS Treat News; 1999 Nov; (No 330):2-4. PubMed ID: 11367171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [AIDS treatment in Africa: the risk of antiretroviral resistance].
    Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric HIV: new opportunities to treat children.
    Van der Linden D; Callens S; Brichard B; Colebunders R
    Expert Opin Pharmacother; 2009 Aug; 10(11):1783-91. PubMed ID: 19558340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV resistance and the developing world.
    Gupta RK; Pillay D
    Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life assessment in HIV clinical research in resource-limited settings: better late than never.
    Becquet R; Burgos-Soto J; Carrieri MP; Spire B
    Trop Med Int Health; 2010 Sep; 15(9):1008-10. PubMed ID: 20561311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa.
    Cooper CL; Mills E; Wabwire BO; Ford N; Olupot-Olupot P
    Int J Infect Dis; 2009 May; 13(3):302-6. PubMed ID: 19004656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV research and access to treatment.
    Warren M
    Science; 2006 Jan; 311(5758):175-6; author reply 175-6. PubMed ID: 16410505
    [No Abstract]   [Full Text] [Related]  

  • 40. The public health approach to antiretroviral treatment (ART) service scale-up in Ethiopia: the first two years of free ART, 2005-2007.
    Assefa Y; Kloos H
    Ethiop Med J; 2008 Oct; 46(4):401-6. PubMed ID: 19271406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.